DelveInsight: HR+/HER2− Breast Cancer Market Projected for Growth
DelveInsight's new market analysis forecasts significant growth for treatments targeting hormone receptor-positive/HER2-negative breast cancer patients through 2036.
Market research firm DelveInsight has released a report detailing the market for treatments of metastatic hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer. The global market, primarily encompassing the United States, EU4 countries, the UK, and Japan, was valued at approximately USD 10 billion in 2023. The report projects this market to rise to approximately USD 14 billion by 2025 and continue growing at an annual rate of about 8% until 2036.
The anticipated growth is attributed to the launch of emerging therapies and an increase in the patient pool diagnosed with HR+/HER2− breast cancer. Key pharmaceutical entities including Merck, Roche, AstraZeneca, and Eli Lilly are identified as major players developing treatments for this patient segment.
Historically, endocrine therapy has been the standard of care for HR+/HER2− breast cancer. In recent years, CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib have demonstrated substantial benefits in extending progression-free survival, particularly in first and second-line settings. Recent advancements include therapies like ORSERDU, specifically indicated for ER+/HER2− tumors with ESR1 mutations, marking a significant therapeutic innovation.
Future treatment landscapes are expected to see the increased adoption of antibody-drug conjugates (ADCs) and oral selective estrogen receptor degraders (SERDs), which will compete with existing CDK4/6 inhibitors. Other therapeutic classes in the pipeline include AKT inhibitors and TROP-2 targeting ADCs. However, the competitive intensity and the uptake of novel SERDs may influence overall market expansion.